The settlement, reached May 26 with Oklahoma Attorney General Mike Hunter, came just two days before the Teva and Johnson & Johnson were scheduled to go to trial.
Mr. Hunter had accused three opioid manufacturers — Purdue Pharma, Johnson & Johnson and Teva — of misleading physicians and patients about the risks associated with the painkillers, which played a significant role in the nationwide epidemic.
Teva is the second company to settle a lawsuit with Oklahoma over the opioid epidemic before the trial. In March, OxyContin maker Purdue Pharma paid $270 million to resolve claims with the state.
Teva said the agreement “does not establish any wrongdoing on the part of the company” and maintains it “has not contributed to the abuse of opioids in Oklahoma in any way.”
J&J will head to court May 28.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.